Johnson Johnson Company Top Insiders

JNJ Stock  USD 155.17  0.33  0.21%   
Nearly 57% of Johnson Johnson's corporate insiders are selling. The analysis of insiders' sentiment of trading Johnson Johnson stock suggests that many insiders are alarmed at this time. Johnson Johnson employs about 131.9 K people. The company is managed by 45 executives with a total tenure of roughly 195 years, averaging almost 4.0 years of service per executive, having 2931.11 employees per reported executive.
Alex Gorsky  Chairman
Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
Joaquin Duato  Chairman
Executive Vice President Worldwide Chairman - Pharmaceuticals

Johnson Johnson's Insider Buying Vs Selling

43

 
Selling
 
Buying

Latest Trades

2024-10-29Tommy TubervilleDisposed @ 160.14
2024-09-10Lloyd DoggettAcquired @ 167.38
2024-09-04John JamesDisposed @ 167.27
2024-08-30Robert J DeckerDisposed 5635 @ 165.06View
2024-08-07C. Scott FranklinAcquired @ 158.9
2024-08-02C. Scott FranklinAcquired @ 164.14
2024-07-16Rick W. AllenDisposed @ 151.01
2024-07-03Sheldon WhitehouseDisposed @ 145.62
2024-07-02Kathy E. ManningAcquired @ 146.03
2024-07-01Jared MoskowitzAcquired @ 146.42
2024-06-21Josh GottheimerDisposed @ 148.74
2024-06-13Rick W. AllenDisposed @ 145.4
2024-06-04Lloyd DoggettAcquired @ 147.8
2024-03-05Lloyd DoggettAcquired @ 159.97
2024-02-16& Johnson JohnsonDisposed 3725 @ 25.81View
2024-02-09Jennifer L TaubertDisposed 59397 @ 156.27View
Monitoring Johnson Johnson's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Johnson Johnson's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Johnson Johnson. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Johnson Johnson's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.

Johnson Johnson's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Johnson Johnson's future performance. Based on our forecasts, it is anticipated that Johnson will maintain a workforce of nearly 131900 employees by December 2024.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Johnson Johnson's latest congressional trading

Congressional trading in companies like Johnson Johnson, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Johnson Johnson by those in governmental positions are based on the same information available to the general public.
2024-11-15Senator Tommy TubervilleAcquired $15K to $50KVerify
2024-11-14Senator Tommy TubervilleAcquired $15K to $50KVerify
2024-10-11Representative Lloyd DoggettAcquired Under $15KVerify
2024-10-10Representative Lloyd DoggettAcquired Under $15KVerify
2024-09-06Representative John JamesAcquired Under $15KVerify
2024-09-02Representative John JamesAcquired Under $15KVerify
2024-08-20Senator Sheldon WhitehouseAcquired $15K to $50KVerify
2024-08-16Representative Kathy ManningAcquired Under $15KVerify
2024-08-08Representative Richard W AllenAcquired $15K to $50KVerify
2024-08-06Representative Jared MoskowitzAcquired Under $15KVerify
2024-07-15Representative Kevin HernAcquired Under $15KVerify
2024-07-10Representative Richard W AllenAcquired $15K to $50KVerify
2024-07-09Representative Josh GottheimerAcquired Under $15KVerify
2024-07-03Representative Lloyd DoggettAcquired Under $15KVerify
2024-04-12Representative Kevin HernAcquired Under $15KVerify
2024-01-24Representative Blake MooreAcquired Under $15KVerify
2024-01-17Senator Jerry MoranAcquired Under $15KVerify
2024-01-16Senator Jerry MoranAcquired Under $15KVerify
2024-01-13Representative Kevin HernAcquired Under $15KVerify
2023-11-16Senator Tommy TubervilleAcquired Under $15KVerify
2023-11-15Senator Tommy TubervilleAcquired Under $15KVerify
2023-10-20Senator Pete RickettsAcquired $100K to $250KVerify
2023-10-13Representative Kevin HernAcquired Under $15KVerify
2023-10-04Representative John CurtisAcquired Under $15KVerify
2023-10-03Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-10-02Senator Sheldon WhitehouseAcquired Under $15KVerify
2023-08-10Representative Richard W AllenAcquired $15K to $50KVerify
2023-07-12Representative Kevin HernAcquired Under $15KVerify
2023-04-10Representative Kevin HernAcquired Under $15KVerify
2023-03-13Representative Lois FrankelAcquired Under $15KVerify
2023-03-11Representative Thomas H KeanAcquired $15K to $50KVerify
2023-02-11Representative Thomas H KeanAcquired $15K to $50KVerify
2023-01-13Representative Kevin HernAcquired Under $15KVerify
2022-12-08Representative Kurt SchraderAcquired Under $15KVerify
2022-11-18Representative Lois FrankelAcquired Under $15KVerify
2022-11-13Senator Shelley Moore CapitoAcquired Under $15KVerify
2022-11-12Senator Shelley Moore CapitoAcquired Under $15KVerify
2022-07-15Representative Kevin HernAcquired Under $15KVerify
2022-07-08Representative John CurtisAcquired Under $15KVerify
2022-06-09Representative Lois FrankelAcquired Under $15KVerify
2022-06-03Representative Cynthia AxneAcquired Under $15KVerify
2022-04-12Representative Kevin HernAcquired Under $15KVerify
2022-03-23Representative John CurtisAcquired Under $15KVerify
2022-02-03Senator Thomas R CarperAcquired Under $15KVerify
2022-02-02Senator Thomas R CarperAcquired Under $15KVerify
2022-01-11Representative Kevin HernAcquired Under $15KVerify
2021-10-18Representative Robert J WittmanAcquired Under $15KVerify
2021-10-07Representative Kevin HernAcquired $50K to $100KVerify
2021-07-17Representative Blake MooreAcquired Under $15KVerify
2021-07-15Representative Alan S LowenthalAcquired Under $15KVerify
2021-07-14Representative Kevin HernAcquired $250K to $500KVerify
2021-06-12Representative Richard W AllenAcquired $15K to $50KVerify
2021-05-06Representative Kathy ManningAcquired Under $15KVerify
2021-02-12Representative Austin ScottAcquired $15K to $50KVerify
2021-02-04Representative Kathy ManningAcquired Under $15KVerify
2020-11-14Representative Kevin HernAcquired Under $15KVerify
2020-09-08Representative K Michael ConawayAcquired $15K to $50KVerify
2020-08-25Representative Bob GibbsAcquired Under $15KVerify
2020-08-10Representative Josh GottheimerAcquired Under $15KVerify
2020-07-31Representative Bill PascrellAcquired $15K to $50KVerify
2020-04-29Senator Shelley Moore CapitoAcquired Under $15KVerify
2020-04-28Senator Shelley Moore CapitoAcquired Under $15KVerify
2020-01-14Representative Mike GallagherAcquired Under $15KVerify
2020-01-03Representative Mikie SherrillAcquired Under $15KVerify
2019-12-20Representative Lois FrankelAcquired Under $15KVerify
2019-02-14Representative John A YarmuthAcquired Under $15KVerify
2018-11-08Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-11-07Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-06-26Representative Earl BlumenauerAcquired Under $15KVerify
2018-06-22Representative Lois FrankelAcquired Under $15KVerify
2017-11-07Senator Tammy DuckworthAcquired Under $15KVerify
2017-07-03Senator James InhofeAcquired $50K to $100KVerify
2016-05-04Senator Shelley Moore CapitoAcquired Under $15KVerify
2016-05-03Senator Shelley Moore CapitoAcquired Under $15KVerify

Johnson Johnson Management Team Effectiveness

The company has Return on Asset of 0.084 % which means that on every $100 spent on assets, it made $0.084 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2089 %, implying that it generated $0.2089 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.25 this year, although the value of Return On Assets will most likely fall to 0.14. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).
The value of Common Stock Shares Outstanding is expected to pull down to about 2.2 B. The value of Net Income Applicable To Common Shares is expected to pull down to about 13 B

Johnson Johnson Workforce Comparison

Johnson Johnson is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 132,796. Johnson Johnson totals roughly 131,900 in number of employees claiming about 99% of equities under Health Care industry.

Johnson Johnson Profit Margins

The company has Net Profit Margin of 0.17 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.770.6882
Moderately Up
Pretty Stable
Net Profit Margin0.430.4128
Sufficiently Up
Slightly volatile
Operating Profit Margin0.180.2749
Way Down
Slightly volatile
Pretax Profit Margin0.170.1769
Sufficiently Down
Pretty Stable
Return On Assets0.140.2098
Way Down
Pretty Stable
Return On Equity0.540.5111
Notably Up
Slightly volatile

Johnson Johnson Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Johnson Johnson insiders, such as employees or executives, is commonly permitted as long as it does not rely on Johnson Johnson's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Johnson Johnson insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
1.0
1
1
 68,835 
 68,835 
2024-09-01
0.8
4
5
 15,935 
 35,906 
2024-06-01
3.2
16
5
 64,664 
 69,533 
2024-03-01
0.9367
74
79
 1,126,871 
 841,041 
2023-12-01
0.5
1
2
 227.97 
 12,388 
2023-09-01
0.25
2
8
 14,927 
 64,213 
2023-06-01
4.3333
13
3
 89,364 
 12,520 
2023-03-01
1.1064
52
47
 1,560,338 
 1,435,117 
2022-12-01
0.0563
17
302
 424,982 
 808,031 
2022-06-01
0.75
6
8
 1,639 
 121,198 
2022-03-01
0.6949
82
118
 1,591,197 
 1,210,521 
2021-12-01
1.0
4
4
 5,804 
 22,640 
2021-06-01
1.5
3
2
 767.89 
 912.00 
2021-03-01
1.3559
80
59
 1,535,897 
 616,920 
2020-12-01
1.0
4
4
 55,444 
 130,274 
2020-09-01
1.4
7
5
 19,996 
 61,230 
2020-03-01
1.0
90
90
 2,022,671 
 1,394,742 
2019-12-01
1.0
3
3
 7,366 
 4,034 
2019-09-01
1.0
1
1
 382.39 
 2,692 
2019-06-01
2.0
2
1
 3,350 
 353.00 
2019-03-01
1.0615
69
65
 1,211,043 
 1,102,350 
2018-12-01
0.7895
15
19
 506,509 
 1,029,964 
2018-09-01
0.2727
3
11
 29,684 
 66,041 
2018-06-01
2.0
2
1
 757.75 
 385.00 
2018-03-01
1.098
56
51
 1,459,455 
 1,396,495 
2017-12-01
1.0
4
4
 76,454 
 119,787 
2017-09-01
1.0
6
6
 288,991 
 575,950 
2017-06-01
4.0
4
1
 1,313 
 409.00 
2017-03-01
1.1077
72
65
 2,208,599 
 1,395,624 
2016-09-01
1.5
6
4
 45,606 
 88,162 
2016-06-01
0.8571
6
7
 8,522 
 23,649 
2016-03-01
1.2292
59
48
 1,810,647 
 1,592,510 
2015-12-01
0.8
8
10
 72,335 
 128,397 
2015-06-01
1.8
9
5
 232,452 
 415,933 
2015-03-01
1.7931
52
29
 1,497,466 
 863,712 
2014-12-01
1.625
13
8
 124,081 
 80,120 
2014-09-01
3.3333
10
3
 31,463 
 60,936 
2014-06-01
1.8571
13
7
 26,671 
 50,018 
2014-03-01
2.2273
49
22
 1,595,007 
 270,290 
2013-12-01
2.0
24
12
 43,879 
 88,621 
2013-09-01
1.5
18
12
 151,479 
 218,390 
2013-06-01
4.5
9
2
 1,681 
 7,429 
2013-03-01
2.8947
55
19
 1,861,702 
 242,918 
2012-12-01
1.3333
24
18
 88,061 
 242,611 
2012-09-01
1.3333
12
9
 359,037 
 708,892 
2012-03-01
3.8
38
10
 2,001,830 
 1,040,386 
2011-12-01
1.4
14
10
 355,881 
 705,544 
2011-06-01
2.0
8
4
 331,325 
 658,300 
2011-03-01
2.8333
34
12
 1,078,290 
 147,164 
2010-12-01
2.4
12
5
 23,846 
 41,538 
2010-09-01
1.5
12
8
 268,351 
 529,534 
2010-06-01
9.0
9
1
 21,323 
 18,000 
2010-03-01
3.3333
30
9
 1,019,440 
 123,426 
2009-12-01
1.3846
18
13
 114,643 
 230,603 
2009-09-01
2.1429
15
7
 188,410 
 411,810 
2009-06-01
2.75
11
4
 41,599 
 80,840 
2009-03-01
2.2381
47
21
 1,229,737 
 244,806 
2008-12-01
2.8571
20
7
 76,055 
 98,292 
2008-09-01
7.0
14
2
 5,454 
 6,000 
2008-06-01
0.5714
20
35
 138,992 
 270,000 
2008-03-01
4.8889
44
9
 1,089,570 
 110,445 
2007-12-01
0.9444
17
18
 32,542 
 59,287 
2007-09-01
11.0
11
1
 2,422 
 2,640 
2007-06-01
14.0
14
1
 4,734 
 1,700 
2007-03-01
4.6667
42
9
 1,050,227 
 237,274 
2006-12-01
0.8095
17
21
 222,057 
 437,806 
2006-09-01
1.4375
23
16
 163,933 
 293,054 
2006-06-01
2.2857
16
7
 22,169 
 51,600 
2006-03-01
7.1429
50
7
 1,414,193 
 45,960 
2005-12-01
2.0
18
9
 72,595 
 95,869 
2005-09-01
2.375
19
8
 18,256 
 30,989 
2005-06-01
4.4
22
5
 68,622 
 109,600 
2005-03-01
3.9
39
10
 1,183,947 
 201,708 
2004-12-01
3.3333
20
6
 8,068 
 10,700 
2004-09-01
1.9167
23
12
 141,147 
 203,523 
2004-06-01
5.5
22
4
 52,068 
 89,200 
2004-03-01
3.4737
66
19
 1,467,963 
 540,524 
2003-12-01
1.0
34
34
 156,218 
 407,761 
2003-09-01
7.3333
22
3
 18,738 
 18,979 
2003-06-01
4.3333
13
3
 3,404 
 125,200 
2003-03-01
1.0
1
1
 26.00 
 13,800 

Johnson Johnson Notable Stakeholders

A Johnson Johnson stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Johnson Johnson often face trade-offs trying to please all of them. Johnson Johnson's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Johnson Johnson's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alex GorskyChairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeProfile
Joaquin DuatoExecutive Vice President Worldwide Chairman - PharmaceuticalsProfile
Jennifer TaubertExecutive Vice President - Worldwide Chairman, PharmaceuticalsProfile
Ashley McEvoyExecutive Vice President - Worldwide Chairman, Medical DevicesProfile
Thibaut MongonExecutive Vice President, Worldwide Chairman, Consumer HealthProfile
Paulus StoffelsWorldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeProfile
Michael SneedExecutive Vice President - Global Corporate Affairs and Chief Communication OfficerProfile
Jasmina BrooksPresident WebsterProfile
Kathryn WengelExecutive Vice President Chief Global Supply Chain OfficerProfile
James SwansonExecutive Vice President, Chief Information OfficerProfile
Joseph WolkChief Financial Officer, Executive Vice PresidentProfile
Peter FasoloChief Human Resource Officer, Executive Vice PresidentProfile
Joseph CPAExecutive CFOProfile
Jennifer DoudnaIndependent DirectorProfile
Marillyn HewsonIndependent DirectorProfile
Mary BeckerleIndependent DirectorProfile
Darius AdamczykIndependent DirectorProfile
Ronald WilliamsIndependent DirectorProfile
Hubert JolyIndependent DirectorProfile
Anne MulcahyLead Independent DirectorProfile
Ian DavisIndependent DirectorProfile
Mark McClellanIndependent DirectorProfile
Charles PrinceIndependent DirectorProfile
Mark WeinbergerIndependent DirectorProfile
Michael UllmannVP, General Counsel and Member of Executive CommitteeProfile
A WashingtonIndependent DirectorProfile
Dirk BrinckmanChief OfficerProfile
Elizabeth JDExecutive OfficerProfile
Duane ArsdaleTreasurerProfile
Michael BodnerGlobal RecoveryProfile
Nadja WestIndependent DirectorProfile
Mark LarkinsWorldwide SecretaryProfile
Vanessa BroadhurstExecutive Vice President Global Corporate AffairsProfile
Hani AbouhalkaCompany DigitalProfile
Ahmet TezelGroup RDProfile
Robert DeckerController OfficerProfile
Mathai MammenExecutive Vice President Pharmaceuticals, R&DProfile
Timothy SchmidExecutive MedTechProfile
Tom CavanaughCompany MedicineProfile
William HaitExecutive Vice President Chief External Innovation, Medical Safety, Global Public Health OfficerProfile
D DavisIndependent DirectorProfile
Jessica MooreVice RelationsProfile
Celine MartinGroup CSSProfile
Elizabeth ForminardExecutive CounselProfile
Guy MDGroup EMEAProfile

About Johnson Johnson Management Performance

The success or failure of an entity such as Johnson Johnson often depends on how effective the management is. Johnson Johnson management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Johnson management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Johnson management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.36  0.38 
Return On Capital Employed 0.19  0.25 
Return On Assets 0.21  0.14 
Return On Equity 0.51  0.54 

Johnson Johnson Workforce Analysis

Traditionally, organizations such as Johnson Johnson use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Johnson Johnson within its industry.

Johnson Johnson Manpower Efficiency

Return on Johnson Johnson Manpower

Revenue Per Employee645.6K
Revenue Per Executive1.9B
Net Income Per Employee101K
Net Income Per Executive296.1M
Working Capital Per Employee54.7K
Working Capital Per Executive160.3M
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.89)
Dividend Share
4.86
Earnings Share
6.05
Revenue Per Share
36.428
Quarterly Revenue Growth
0.052
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.